scholarly journals HPV Vaccines: Current Status

2016 ◽  
pp. 1
Author(s):  
Mustafa Erkan Sarı ◽  
Mehmet Mutlu Meydanlı
Keyword(s):  
Cervical Cancer ◽  
Dose Schedule ◽  
Genital Warts ◽  
Hpv Infection ◽  
World Health ◽  
Quadrivalent Vaccine ◽  
Current Status ◽  
Hpv Vaccines ◽  
Cervical Lesions ◽  
Hpv Types

<p><strong>Abstract</strong></p><p>Cervical cancer is the fourth most common cancer in women worldwide, and the main cause is Human Papillomavirus (HPV) infection. HPV vaccines have had dramatic impacts on the prevalence of targeted HPV types (6,11,16 and 18), genital warts and precancerous cervical lesions. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have confirmed the safety of HPV vaccines after &gt;250 million doses were administered worldwide. WHO approved the two-dose-schedule of HPV vaccines in females younger than 15 years of age, with ≥6 month intervals. Extension of vaccination to men could further reduce the population prevalence of HPV and provide direct protection of men against genital warts and anal, penile and oropharyngeal cancers. The nine-valent HPV vaccine has demonstrated equivalent protection against the four types in the quadrivalent vaccine and high efficacy against the next five commonest causes of cervical cancer (HPV types 31,33,45,52 and 58). The Advisory Committee on Immunization Practices (ACIP) recommends the nine-valent vaccine and it has been approved by the FDA in 2014 for both genders between 11–12 years of age.</p><p> </p>

scholarly journals Current studies on human papillomavirus in Saudi Arabia

2015 ◽  
Vol 9 (06) ◽  
pp. 571-576 ◽  
Author(s):  
Fatimah Saeed Alhamlan ◽  
Ahmed A Al-Qahtani ◽  
Mohammed N Al-Ahdal
Keyword(s):  
Cervical Cancer ◽  
Saudi Arabia ◽  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Infection ◽  
World Health ◽  
Cervical Lesions ◽  
Hpv Types ◽  
Health Organization ◽  
Low Prevalence

Human papillomavirus (HPV) infection is a significant etiological factor and an important prognosticator in cervical cancer. Indeed, researchers worldwide have confirmed these roles for high-risk HVPs in over 70% of cervical cancer cases. According to the World Health Organization, approximately 561,200 new cancer cases (5.2% of all new cancers) are attributed to HPV infection. Over 120 types of HPV are classified further as either low-risk HPV (LR-HPV) or high-risk HPV (HR-HPV) based on their oncological potential of transforming cells. The LR-HPV types cause benign hyperproliferative lesions (i.e. genital warts) while the HR-HPV types are strongly associated with premalignant and malignant cervical lesions. Data on the prevalence of HPV, survival of infected patients, and mortality rate are scarce in Saudi Arabia. The unsubstantiated assumption of a low prevalence of HPV in Saudi Arabia has contributed to limiting HPV research in this conservative country. Therefore, the goal of this review is to shed light on the current HPV research being conducted and the prevalence of HPV in Saudi Arabia.

scholarly journals Prevalence of Human Papillomavirus (HPV) infection in women living in remote riverine communities in the Amazonas, Brazil

2019 ◽  
Author(s):  
Marco Antonio Zonta ◽  
Karina Bonilha Roque ◽  
Yara Juliano ◽  
Anne Liljander ◽  
Markus Cavalar ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Infection ◽  
Public Health Services ◽  
Cervical Lesions ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Remote Areas ◽  
Hpv Types ◽  
Crucial Part

Abstract Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Since some HPV types are associated with the development of cervical cancer, routine screening for HPV plays a crucial part in cancer prevention programs at global level. In Brazil, the cervical cancer rate is among the highest in the world, in particular in indigenous women living in remote areas with limited access to public health services. The objective of this study was to determine the prevalence of HPV infections and their co-occurrence with cervical lesions in Brazilian women living in isolated riverine communities. Moreover, the association between social environment, sexual activity and prevalence of HPV infection was assessed.

scholarly journals High prevalence of Human Papillomavirus (HPV) type 66 in low-grade cervical lesions of Mexican women

2020 ◽  
Author(s):  
Karina Juárez-González ◽  
Vladimir Paredes-Cervantes ◽  
Silvia Gordillo-Rodríguez ◽  
Saúl González-Guzmán ◽  
Xochilt Moncayo-Valencia ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cervical Cancer ◽  
Transmitted Disease ◽  
Low Grade ◽  
Mexican Women ◽  
Cervical Lesions ◽  
Hpv 16 ◽  
High Prevalence ◽  
Hpv Types ◽  
Intraepithelial Lesions

AbstractBackgroundHPV-16 infections constitute the highest risk for developing uterine cervix cancer. However, the role of other high-risk types is still controversial.ObjectiveTo analyze HR-HPV prevalence and its possible associations between HPV and risk factors related to cervical lesions among Mexican women.MethodsCross sectional study using 362 cervical samples collected between 2016 and 2017. Fourteen HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) were detected by highly sensitive PCR amplification followed by reverse hybridization. Bivariate and multivariate analyses were performed to investigate the association between HPV types and risk factors among lesions.ResultsMost samples were HR-HPV positive (83.43%). HPV-16 was the most prevalent infection among negative for intraepithelial lesions or malignancy (78.6%), high-grade squamous intraepithelial lesions (50%), and cervical cancer (58.2%). HPV-66 showed an unexpected high prevalence in atypical squamous cells of undetermined significance (50%), low-grade squamous intraepithelial (45.7%), and only found in 3.6% of cervical cancers. HPV-16 was significantly prevalent among women between 30-39 years, whereas types 66 and 52 were significantly associated when previously sexually transmitted disease had occurred (p< 0.05).ConclusionsHPV-66 either in single or co-infection with other HR-HPV types (excluding 16 and 18) might be indicative of non-progressive cancer lesions. HPV-66 prevalence was unusually high in low-grade cervical lesions, predominantly in co-infection with HPV-51, and very low among cervical cancer. This should be addressed to interpret results obtained by methods that group type 66 with other HR-types.

scholarly journals Distribution and Prevalence of High-Risk Human Papillomavirus Genotypes in Cervical Specimens

2020 ◽  
Vol 25 (3) ◽  
pp. 325-331
Author(s):  
Erkan Özmen ◽  
Ülkü Altoparlak ◽  
Muhammet Hamidullah Uyanık ◽  
Abdulkadir Gülen
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Age Groups ◽  
Hpv Infection ◽  
High Rate ◽  
Genotype Distribution ◽  
Hpv Dna ◽  
Hpv Test ◽  
Significant Difference ◽  
Hpv Types

Introduction: Human papillomavirus (HPV) is frequently a sexually transmitted virus and can cause cervical cancer in women. Cervical cancer is the second most common type of cancer among the developing countries. In this study, cervical HPV DNA positivity and genotype distributions were investigated in female patients living in our region and the results were compared with different studies. Materials and Methods: Between 1 July, 2017 and 1 March, 2019, 433 cervical swabs were sent to Ataturk University, Medical Faculty Hospital, Medical Microbiology Laboratory due to suspicion of HPV. Swab samples were evaluated for HPV virus using molecular (Polymerase Chain Reaction-PCR) methods. For this purpose, Xpert HPV Test (Cepheid, Inc, Sunnyvale, CA) was used to identify HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 t in a single sample. Results: Mean age of the patients ranged from 20 to 69 years, with a mean of 39.8 years (± 10.0). Positivity was detected in 62 of the 433 patients. Mean age of the positive patients was 40.2 years (± 11.3). When the positive patients were examined in terms of HPV types, the presence of HPV 16 was observed with a rate of 25.6%, while the HPV 18/45 types were found to be 9.0% in total. When patients were evaluated according to age groups, HPV DNA positivity was highest in the 25-34 age group with 38.7%. In our statistical study, there was no significant difference in HPV DNA positivity rate between the ages of 35 and under 35 years. Conclusion: This study demonstrates the prevalence and viral genotype distribution of HPV infection in women in Erzurum region. HPV type 16 is seen with a high rate in our region.

Human papillomavirus vaccination: evidence base for efficacy and safety

GYNECOLOGY ◽  
2021 ◽  
Vol 23 (2) ◽  
pp. 125-130
Author(s):  
Yuliya E. Dobrokhotova ◽  
Ekaterina I. Borovkova
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Intraepithelial Neoplasia ◽  
Evidence Base ◽  
Hpv Infection ◽  
Efficacy And Safety ◽  
Human Papillomavirus Vaccination ◽  
Hpv Types ◽  
Further Development

The article provides a literature review on the prevention of cervical cancer by human papillomavirus (HPV) vaccination. Currently, 3 vaccines are available: the 4-valent vaccine against HPV types 6, 11, 16 and 18, the 9-valent vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 and the bivalent vaccine against HPV types 16 and 18. Vaccination provides protection for women and men against infection with HPV and further development of HPV-associated diseases. Following immunization, seroconversion develops in 93-100% of women and in 99-100% of men and is effective in preventing incident and persistent HPV infection as well as cervical intraepithelial neoplasia. HPV immunization is ineffective in treating an existing HPV infection, genital warts, or anogenital intraepithelial neoplasia. HPV vaccination status does not affect recommendations for cervical cancer screening.

scholarly journals Associations among Serum Lipocalin-2 Concentration, Human Papilloma Virus, and Clinical Stage of Cervical Cancer

Medicina ◽  
2019 ◽  
Vol 55 (6) ◽  
pp. 229 ◽  
Author(s):  
Agnė Vitkauskaitė ◽  
Joana Celiešiūtė ◽  
Saulius Paškauskas ◽  
Erika Skrodenienė ◽  
Rūta Jolanta Nadišauskienė ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papilloma Virus ◽  
Clinical Stage ◽  
Stage Iv ◽  
Hpv Infection ◽  
Control Group ◽  
Lipocalin 2 ◽  
Papilloma Virus ◽  
Tissue Biopsy ◽  
Hpv Types

Background and objective: Lipocalin 2 (LCN2) has an oncogenic role in promoting tumorigenesis through enhancing tumor cell proliferation and the metastatic potential. The aim of our study was to determine whether serum LCN2 could serve as a diagnostic marker of cervical cancer (CC) and to evaluate the correlation between its serum concentration, the clinical stage of the cancer and Human Papilloma Virus HPV infections in women. Materials and methods: A total of 33 women with histologically proven cervical cancer (CC), 9 women with high- grade cervical intraepithelial neoplasia (HSIL) and 48 healthy women (NILM) were involved in the study. A concentration of LCN2 was assayed with the Magnetic LuminexR Assay multiplex kit. An HPV genotyping kit was used for the detection and differentiation of 15 high-risk (HR) HPV types in the liquid-based cytology medium (LBCM) and the tissue biopsy. Results: The majority (84.8%) of the women were infected by HPV16 in the CC group, and there was no woman with HPV16 in the control group (P < 0.01). Several types of HR HPV were found more often in the LBCM compared to in the tissue biopsy (P = 0.044). HPV16 was more frequently detected in the tissue biopsy than the LBCM (P < 0.05). The LCN2 level was higher in HPV-positive than in HPV-negative women (P = 0.029). The LCN2 concentration was significantly higher in women with stage IV than those with stage I CC (P = 0.021). Conclusions: Many HR HPV types, together with HPV16/18, can colonize the vagina and cervix, but often HPV16 alone penetrates into the tissue and causes CC. The serum LCN2 concentration was found to be associated not only with HR HPV infection, irrespective of the degree of cervical intraepithelial changes, but also with advanced clinical CC stage. LCN2 could be used to identify patients with advanced disease, who require a more aggressive treatment.

scholarly journals Human papillomavirus and abnormal cervical lesions among HIV-infected women in HIV-discordant couples from Kenya

2020 ◽  
Vol 96 (6) ◽  
pp. 457-463 ◽  
Author(s):  
Brandon L Guthrie ◽  
Anne F Rositch ◽  
Joy Alison Cooper ◽  
Carey Farquhar ◽  
Rose Bosire ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Infection ◽  
Cervical Neoplasia ◽  
Cervical Cytology ◽  
High Grade ◽  
Cervical Lesions ◽  
Hpv Prevalence ◽  
High Grade Lesion ◽  
Hpv Types ◽  
Hpv Screening

ObjectiveHIV infection increases the risk of high-grade cervical neoplasia and invasive cervical carcinoma. The study addresses the limited data describing human papillomavirus (HPV) infection and cervical neoplasia among HIV-infected women in HIV-discordant relationships in sub-Saharan Africa, which is needed to inform screening strategies.MethodsA cross-sectional study of HIV-infected women with HIV-uninfected partners was conducted to determine the distribution of type-specific HPV infection and cervical cytology. This study was nested in a prospective cohort recruited between September 2007 and December 2009 in Nairobi, Kenya. Cervical cells for HPV DNA testing and conventional cervical cytology were collected. HPV types were detected and genotyped by Roche Linear Array PCR assay.ResultsAmong 283 women, the overall HPV prevalence was 62%, and 132 (47%) had ≥1 high-risk (HR)-HPV genotype. Of 268 women with cervical cytology results, 18 (7%) had high-grade cervical lesions or more severe by cytology, of whom 16 (89%) were HR-HPV-positive compared with 82 (41%) of 199 women with normal cytology (p<0.001). The most common HR-HPV types in women with a high-grade lesion or more severe by cytology were HPV-52 (44%), HPV-31 (22%), HPV-35 (22%), HPV-51 (22%) and HPV-58 (22%). HR-HPV genotypes HPV-16 or HPV-18 were found in 17% of women with high-grade lesions or more severe. HR-HPV screening applied in this population would detect 89% of those with a high-grade lesion or more severe, while 44% of women with normal or low-grade cytology would screen positive.ConclusionHR-HPV prevalence was high in this population of HIV-infected women with an uninfected partner. Choice of screening for all HR genotypes versus a subset of HR genotypes in these HIV-infected women will strongly affect the performance of an HPV screening strategy relative to cytological screening. Regional and subpopulation differences in HR-HPV genotype distributions could affect screening test performance.

scholarly journals Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines

2005 ◽  
Vol 192 (7) ◽  
pp. 1158-1165 ◽  
Author(s):  
Fabián Méndez ◽  
Nubia Muñoz ◽  
Héctor Posso ◽  
Mónica Molano ◽  
Victor Moreno ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccines ◽  
Hpv Types
Sign in / Sign up

Export Citation Format

Share Document